American College of Radiology and other colorectal care advocacy agencies lobby Congress to pass Medicare coverage for CT colonography screening

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE AMERICAN COLLEGE OF RADIOLOGY and several colorectal cancer care advocacy groups urged Congress to pass the CT Colonography Screening for Colorectal Cancer Act, which would provide Medicare coverage for seniors who choose those screening exams.

“A third of those who should be screened for colorectal cancer can’t have or won’t get a colonoscopy. CT colonography increases screening rates where offered. Medicare coverage would provide seniors with insured access to an exam that may appeal to them. This would jump-start screening, catch more cancers early and saves more lives,” said Eric Hargis, CEO of Colon Cancer Alliance. Other advocacy groups included the Prevent Cancer Foundation, Chris4Life Colon Cancer Foundation, the Colon Cancer Coalition, and Fight Colorectal Cancer.

Several major insurers cover screening with virtual colonoscopy, and more than 20 states require insurers to cover these exams. However, Medicare does not cover beneficiaries for CT colonography.

In recent draft recommendations, the U.S. Preventive Services Task Force named virtual colonoscopy an alternative screening exam; the task force did not grade specific screening exams. The American Cancer Society strongly supported CT colonography in its comments to the task force on those draft recommendations. The ACR has urged the task force to reclassify CT colonography as a recommended screening exam.

THE TISCH CANCER INSTITUTE at the Icahn School of Medicine at Mount Sinai and CTI BioPharma Corp. established a $1.5 million research endowment fund, the CTI BioPharma International Postdoctoral Research Fellowship, for international collaboration in translational research in hematology and immunobiology.

The fellowship and endowment will provide seed funding to young physician researchers. Mount Sinai will receive endowment funding over three years to identify and select research projects from medical researchers currently working at international institutions based outside the U.S.

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login